CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares

Rhea-AI Summary

Hemostemix (TSXV: HEM) (OTC: HMTXF) announced that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at $0.295 per share, resulting in the issuance of 1,634,466 Common Shares. The transaction is subject to TSXV Exchange approval.

Following the Hemostemix technology transfer presentation at CytoImmune's Innovations & Investment Conference, CytoImmune plans to present Hemostemix's clinical trial results to various medical practitioners in Puerto Rico. The initiative aims to treat no-option patients under a special access program, demonstrate patient improvements, and track healthcare cost reductions. The company highlighted potential revenue opportunities for medical practitioners, stating that implementing four ACP-01 procedures daily could generate additional income of $1,000,000, with each treatment unit priced at $37,000.

Positive

• Secured USD $336,500 investment from CytoImmune through private placement
• Each ACP-01 treatment unit priced at $37,000
• Potential revenue stream through medical practitioner adoption

Negative

• Share dilution through issuance of 1,634,466 new common shares
• Transaction subject to regulatory approval

Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at today's closing price of $0.295 ($336,500 / $0.69789 = $482,167.68) (1,634,466 Common Shares), subject to the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025.

"The Hemostemix technology transfer was highlighted at CytoImmune's Innovations & Investment in Health and Biotechnology Conference, and this investment is further evidence of our strong and vibrant relationship. Next, at CytoImmune, we plan to present Hemostemix's clinical trial results to Puerto Rico's cardiologists, thoracic surgeons, vascular surgeons, podiatrists, chiropodists, and family practitioners. Our objectives are many fold:

1. Treat no-option patients under a special access program;

2. Demonstrate patients' improvements;

3. Track the decrease in healthcare costs over a healthcare budget period;

4. Demonstrate to physicians how they can augment their incomes:

For example, a medical practitioner who adds four ACP-01 procedures per day may generates an additional $1,000,000 of income for his practice. One physician who adds four ACP-01 procedures per day generates 80 treatments per month, at $37,000 per unit," Smeenk said.

About Hemostemix

Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix is focused on scaling angiogenic, neuronal, and cardiomyocyte cell precursors, to treat no-option patients worldwide.

Learn more: www.hemostemix.com

Contact: Thomas Smeenk, President & CEO - tsmeenk@hemostemix.com | (905) 580-4170 Stock Information: TSXV: HEM | OTC: HMTXF | FSE: 2VF0

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239651

FAQ

How much is CytoImmune investing in Hemostemix (HMTXF) through the private placement?

CytoImmune is investing USD $336,500 through a non-brokered private placement at $0.295 per share.

How many new common shares will Hemostemix (HMTXF) issue in the February 2025 private placement?

Hemostemix will issue 1,634,466 new common shares through the private placement.

What is the price per treatment unit for Hemostemix's (HMTXF) ACP-01 procedure?

Each ACP-01 treatment unit is priced at $37,000.

What potential revenue can medical practitioners generate from Hemostemix's (HMTXF) ACP-01 procedures?

Medical practitioners performing four ACP-01 procedures per day could potentially generate an additional $1,000,000 in practice income.